Comparative analysis of gene expression between renal cortex and papilla in nedaplatin-induced nephrotoxicity in rats

Human and Experimental Toxicology

Volumn 26, Issue 10, 2007, Pages 767-780

  Uehara, Takeki ^a   Miyoshi, Takako ^a   Tsuchiya, Noriko ^a   Masuno, Koichi ^a   Okada, Manabu ^a   Inoue, Satoshi ^a   Torii, Mikinori ^a   Yamate, Jyoji ^b   Maruyama, Toshiyuki ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b Osaka Prefecture University   (Japan)

Author keywords

Cytokeratin; Gene expression; Nedaplatin; Renal papillary toxicity; Toxicogenomics

Indexed keywords

CYTOKERATIN; GLUTAREDOXIN; GLUTAREDOXIN 1; GLUTATHIONE TRANSFERASE; HEME OXYGENASE; METALLOTHIONEIN; METALLOTHIONEIN IA; NEDAPLATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE REGULATION; CELL DEATH; CELL HYPERPLASIA; CELL MIGRATION; CONTROLLED STUDY; DNA METABOLISM; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY INJURY; KIDNEY PAPILLA; MALE; MICROARRAY ANALYSIS; NEPHROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; GENE EXPRESSION PROFILING; KERATIN-14; KERATIN-19; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; ORGANOPLATINUM COMPOUNDS; RATS; RATS, WISTAR; RNA, MESSENGER;

RATTUS; RATTUS NORVEGICUS;

EID: 36849080818     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1177/0960327107084069     Document Type: Article

References (68)

1. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother 2003; 4: 889-901.
2. Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: a review of some recent research. Food Chem Toxicol 2006; 44: 1173-83.
3. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2006; 2: 80-91.
4. Boulikas T, Vougiouka M. Cisplatin and platinum drugs at the molecular level. Oncol Rep 2003; 10: 1663-82.
5. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N. Phase II study of (glycolato-O,O) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990; 26: 393-6.
6. Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, Yoshida O, Aso Y. Phase II study of cis-diammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 1992; 31: 187-92.
7. Sugeno K, Mizojiri K, Okabe H, Esumi Y, Takaichi M, Okada Y. Studies on the disposition of a new antineoplastic agent, cis-diammine(glycolato)platinm (254-S) (I) Distribution and excretion of platinum in rats. Iyakuhin Kenkyu 1991; 22: 231-42.
8. Kawai Y, Taniuchi S, Okahara S, Nakamura M, Gemba M. Relationship between cisplatin or nedaplatin-induced nephrotoxicity and renal accumulation. Biol Pharm Bull 2005; 28: 1385-8.
9. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR. Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 1995; 48: 761-70.
10. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH. Metabolism of Cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 2003; 14: 1-10.
11. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 1980; 213: 551-6.
12. Dobyan DC, Hill D, Lewis T, Bulger RE. Cyst formation in rat kidney induced by cis-platinum administration. Lab Invest 1981; 45: 260-8.
13. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, Flamenbaum W, Trump BF. Cis-diamminedichlorplatinum-induced acute renal failure in the rat. Kidney Int 1982; 21: 54-64.
14. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, Yamate J, Maruyama T. Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 2005; 79: 451-60.
15. Tanaka H, Nagasaki T, Okabe H, Uchida N, Norikura R, Inazawa K, Yamauchi A, Katsuyama Y, Segawa K, Murakami T, Adachi Y, Mizojiri K, Matsubara T, Kawai K, Akaboshi M. Studies on the disposition of a new antineoplastic agent, nedaplatin. Whole-body autoradiography, blood concentration and excretion of [195mPt]nedaplatin following intravenous administration in rats. Iyakuhin Kenkyu 1995; 26: 887-95.
16. Nonclercq D, Toubeau G, Laurent G, Tulkens PM, Heuson-Stiennon JA. Tissue injury and repair in the rat kidney after exposure to cisplatin or carboplatin. Exp Mol Pathol 1989; 51: 123-40.
17. Bulger RE, Dobyan DC. Proliferative lesions found in rat kidneys after a single dose of cisplatin. J Natl Cancer Inst 1984; 73: 1235-42.
18. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, Sternberg SS. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer 1977; 39: 1362-71.
19. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978; 41: 1274-81.
20. Tanaka H, Ishikawa E, Teshima S, Shimizu E. Histopathological study of human cisplatin nephropathy. Toxicol Pathol 1986; 14: 247-57.
21. Dennis G Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4: P3.
22. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
23. Megyesi J, Safirstein RL, Price PM. Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 1998; 101: 777-82.
24. Boverhof DR, Zacharewski TR. Toxicogenomics in risk assessment: applications and needs. Toxicol Sci 2006; 89: 352-60.
25. Orphanides G. Toxicogenomics: challenges and opportunities. Toxicol Lett 2003; 11: 145-8.
26. Fielden MR, Zacharewski TR. Challenges and limitations of gene expression profiling in mechanistic and predictive toxicology. Toxicol Sci 2001; 60: 6-10.
27. Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 1994; 203: 1175-80.
28. Baliga R, Zhang Z, Baliga M, Ueda N, Shah SV. In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 1998; 53: 394-401.
29. Matsushima H, Yonemura K, Ohishi K, Hishida A. The role of oxygen free radicals in cisplatin-induced acute renal failure in rats. J Lab Clin Med 1998; 131: 518-26.
30. Kawai Y, Nakao T, Kunimura N, Kohda Y, Gemba M. Relationship of intracellular calcium and oxygen radicals to Cisplatin-related renal cell injury. J Pharmacol Sci 2006; 100: 65-72.
31. Taguchi T, Nazneen A, Abid MR, Razzaque MS. Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 2005; 148: 107-21.
32. Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology 2004; 195: 221-30.
33. Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 2005; 212: 116-23.
34. Saleh S, El-Demerdash E. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic Clin Pharmacol Toxicol 2005; 97: 91-7.
35. Ajith TA, Usha S, Nivitha V. Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 2007; 375: 82-6.
36. De Witt LM, Jones TW, Moore L. Stimulation of the renal endoplasmic reticulum calcium pump: a possible biomarker for platinate toxicity. Toxicol Appl Pharmacol 1988; 92: 157-69.
37. Shiraishi F, Curtis LM, Truong L, Poss K, Visner GA, Madsen K, Nick HS, Agarwal A. Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol Renal Physiol 2000; 278: F726-36.
38. Kurota H, Yamaguchi M. Suppressed expression of calcium-binding protein regucalcin mRNA in the renal cortex of rats with chemically induced kidney damage. Mol Cell Biochem 1995; 151: 55-60.
39. Huang Q, Dunn RT 2nd, Jayadev S, DiSorbo O, Pack FD, Farr SB, Stoll RE, Blanchard KT. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci 2001; 63: 196-207.
40. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968; 61: 748-55.
41. Bauer M, Bauer I. Heme oxygenase-1: redox regulation and role in the hepatic response to oxidative stress. Antioxid Redox Signal 2002; 4: 749-58.
42. Takahashi T, Morita K, Akagi R, Sassa S. Protective role of heme oxygenase-1 in renal ischemia. Antioxid Redox Signal 2004; 6: 867-77.
43. Chubatsu LS, Meneghini R. Metallothionein protects DNA from oxidative damage. Biochem J 1993; 291: 193-8.
44. Miles AT, Hawksworth GM, Beattie JH, Rodilla V. Induction, regulation, degradation, and biological significance of mammalian metallothioneins. Crit Rev Biochem Mol Biol 2000; 35: 35-70.
45. Hagrman D, Goodisman J, Dabrowiak JC, Souid AK. Kinetic study on the reaction of cisplatin with metallothionein. Drug Metab Dispos 2003; 31: 916-23.
46. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem 1989; 264: 13963-6.
47. Holmgren A, Aslund F. Glutaredoxin. Meth Enzymol 1995; 252: 283-92.
48. Hayes JD, Strange RC. Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic Res 1995; 22: 193-207.
49. Kaplan G, Totsuka A, Thompson P, Akatsuka T, Moritsugu Y, Feinstone SM. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J 1996; 15: 4282-96.
50. McIntire JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT, DeKruyff RH. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immun 2001; 2: 1109-16.
51. Kumanogoh A, Marukawa S, Suzuki K, Takegahara N, Watanabe C, Ch'ng E, Ishida I, Fujimura H, Sakoda S, Yoshida K, Kikutani H. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 2002; 419: 629-33.
52. Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, Freeman GJ, Kuchroo VK. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536-41.
53. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286: F552-63.
54. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290: F517-29.
55. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271: 509-12.
56. Wuthrich RP. The complex role of osteopontin in renal disease. Nephrol Dial Transplant 1998; 13: 2448-50.
57. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 2001; 60: 1645-57.
58. Thukral SK, Nordone PJ, Hu R, Sullivan L, Galambos E, Fitzpatrick VD, Healy L, Bass MB, Cosenza ME, Afshari CA. Prediction of nephrotoxicant action and identification of candidate toxicity-related biomarkers. Toxicol Pathol 2005; 33: 343-55.
59. Aulitzky WK, Schlegel PN, Wu DF, Cheng CY, Chen CL, Li PS, Goldstein M, Reidenberg M, Bardin CW. Measurement of urinary clusterin as an index of nephrotoxicity. Proc Soc Exp Biol Med 1992; 199: 93-6.
60. Eti S, Cheng CY, Marshall A, Reidenberg MM. Urinary clusterin in chronic nephrotoxicity in the rat. Proc Soc Exp Biol Med 1993; 202: 487-90.
61. Rosenberg ME, Silkensen JR. Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995; 27: 633-45.
62. Schwochau GB, Nath KA, Rosenberg ME. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties. Kidney Int 1998; 53: 1647-53.
63. Girton RA, Sundin DP, Rosenberg ME. Clusterin protects renal tubular epithelial cells from gentamicin-mediated cytotoxicity. Am J Physiol Renal Physiol 2002; 282: F703-9.
64. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24.
65. Moll R. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. Subcell Biochem 1998; 31: 205-62.
66. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology 2002; 40: 403-39.
67. Cooper D, Schermer A, Sun TT. Classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications, and limitations. Lab Invest 1985; 52: 243-56.
68. Skinnider BF, Folpe AL, Hennigar RA, Lim SD, Cohen C, Tamboli P, Young A, de Peralta-Venturina M, Amin MB. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol 2005; 29: 747-54.